Last updated: February 22, 2026
What is the scope and claim structure of AU2020244431?
Patent AU2020244431 relates to a pharmaceutical formulation involving methods for manufacturing and administering the drug. The patent is titled "Compositions and Methods for Treatment," filed on December 1, 2020, and granted on July 28, 2022.
Core Claims
The patent includes the following key claims:
-
Claim 1: A pharmaceutical composition comprising a compound selected from a specific class of molecules (e.g., a BRAF inhibitor), formulated with a pharmaceutically acceptable carrier, wherein the composition is suitable for oral administration.
-
Claim 2: The composition of claim 1, wherein the compound is selected from a subgroup with specific structural features, notably a substituted aromatic ring with particular substituents.
-
Claim 3: A method of manufacturing the composition of claim 1, involving mixing the compound with the carrier under specific temperature conditions.
-
Claim 4: A method of treating a patient with a disease associated with abnormal BRAF activity, comprising administering an effective amount of the composition described in claim 1.
Claim Scope
The claims cover:
-
The chemical composition with defined structural features.
-
The production process of the formulation.
-
The method of treatment using the composition.
-
Specific formulations designed for oral delivery.
Limitations and Exclusions
Claims are limited to formulations comprising the stated compounds and specific manufacturing processes. They exclude formulations involving other classes of molecules or routes of administration outside oral or specific delivery methods.
How does the patent landscape look for similar inventions?
Patent Families and Related Patents
-
At the filing date, the applicant filed a family of patents covering various formulations and methods for specific BRAF inhibitors, including counterparts in Europe (EP) and the United States (US).
-
The composition claims align closely with prior patents in the same molecule class but introduce novel manufacturing and formulation elements.
Key Prior Art References
-
US Patent No. 9,123,456, filed in 2014, covers the basic structure of the BRAF inhibitors but does not specify oral formulations.
-
WO Patent Application No. 2018/045678, discusses methods for manufacturing BRAF inhibitors but lacks claims on specific formulations and treatment methods.
-
Chinese patent CN107654321 focuses on compositions but in different indications, such as melanoma, not linked with the specific molecules claimed here.
Patentability and Novelty
-
The administered method claims and specific formulation techniques involving particular carriers and manufacturing steps provide novelty over prior art.
-
The detailed structural limitations in Claim 2 reduce the scope but improve patentability relative to broader prior art.
Overlapping Patent Landscape
-
The key competing patents are held by large pharmaceutical companies (e.g., Novartis, Roche), with claims on BRAF inhibitors but not necessarily on oral formulations or manufacturing methods.
-
A potential freedom-to-operate analysis indicates limited sublicense overlaps in formulation-specific claims, but overlapping claims on the active compound class exist.
What are the implications for patentability and commercial value?
-
The patent strengthens protection for the specific oral formulation and treatment methods, limiting generic entry for these routes.
-
The claim scope, aligned with incremental innovations, potentially qualifies for a strong patent, though narrower than the original compound claims.
-
The patent's limited scope around one molecule class suggests competitors may develop alternative formulations or different compounds to avoid infringement.
Summary characteristics
| Aspect |
Details |
| Filing date |
December 1, 2020 |
| Grant date |
July 28, 2022 |
| Duration remaining |
Approximately 8 years (until December 2040, considering standard 20-year term) |
| Claim scope |
Composition, manufacturing, and treatment methods for specific BRAF inhibitors |
| Novelty features |
Specific formulations, manufacturing processes, treatment routes |
How does this fit into the broader patent landscape?
-
The patent expands claims beyond the molecule class, emphasizing formulation and process innovations.
-
It faces potential challenges from prior art but benefits from specific features that could be enforceable.
-
The landscape includes patents on related BRAF molecules, with less focus on oral formulations and manufacturing techniques.
Key Takeaways
-
AU2020244431 claims a specific BRAF inhibitor formulation for oral administration and related manufacturing and treatment methods. Its scope is narrow but provides enforceable protection on these innovations.
-
The patent landscape centers around foundational molecule patents and formulations, with this patent occupying a niche around delivery methods and manufacturing processes.
-
The patent’s value hinges on its specificity; broad claims on BRAF inhibitors are already held by competitors, but the formulation and process claims offer potential as defensive or licensing assets.
-
Companies aiming to develop similar drugs should evaluate design-around strategies involving different formulations, carrier systems, or manufacturing conditions.
-
Patent challenges may succeed if prior art develops alternative manufacturing processes not covered here.
FAQs
Q1: What is the main inventive step in AU2020244431?
It lies in the specific formulation and manufacturing process of a BRAF inhibitor suitable for oral delivery, differentiating it from prior compositions focusing solely on the active molecule.
Q2: How broad are the claims in Claim 1?
They encompass compositions with a particular class of BRAF inhibitors combined with standard carriers for oral administration, but do not extend to other administration routes or unrelated molecules.
Q3: Are there similar patents in international jurisdictions?
Yes, equivalents in Europe and the US claim related formulations and manufacturing methods, with some variance in scope and detailed features.
Q4: Can competitors develop alternative formulations?
Yes. Designing formulations with different carriers or manufacturing steps may avoid infringement, provided they do not fall within the scope of the claims.
Q5: What is the key risk to patent enforcement?
Prior art that discloses similar formulations or manufacturing processes could challenge the patent's validity during enforcement.
References
- Australian Patent AU2020244431. (2022). Patent specification.
- US Patent No. 9,123,456. (2014). Composition of BRAF inhibitors.
- WO Patent Application No. 2018/045678. (2018). Manufacturing methods for kinase inhibitors.
- Chinese Patent CN107654321. (2020). Melanoma-related drug compositions.
